23 53

Cited 0 times in

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

DC FieldValueLanguage
dc.contributor.author정준-
dc.date.accessioned2021-01-19T08:03:24Z-
dc.date.available2021-01-19T08:03:24Z-
dc.date.issued2020-12-
dc.identifier.issn0960-9776-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181441-
dc.description.abstractPurpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study. Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs). Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common. Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfBREAST-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleA nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorMin Ho Park-
dc.contributor.googleauthorSoo Jung Lee-
dc.contributor.googleauthorWoo Chul Noh-
dc.contributor.googleauthorChang Wan Jeon-
dc.contributor.googleauthorSeok Won Lee-
dc.contributor.googleauthorGil Soo Son-
dc.contributor.googleauthorByung-In Moon-
dc.contributor.googleauthorJin Sun Lee-
dc.contributor.googleauthorSung Soo Kang-
dc.contributor.googleauthorYoung Jin Suh-
dc.contributor.googleauthorGeumhee Gwak-
dc.contributor.googleauthorTae Hyun Kim-
dc.contributor.googleauthorYoung Bum Yoo-
dc.contributor.googleauthorHyun-Ah Kim-
dc.contributor.googleauthorMin Young Kim-
dc.contributor.googleauthorJu Yeon Kim-
dc.contributor.googleauthorJoon Jeong-
dc.identifier.doi10.1016/j.breast.2020.09.004-
dc.contributor.localIdA03727-
dc.relation.journalcodeJ00400-
dc.identifier.eissn1532-3080-
dc.identifier.pmid32980648-
dc.subject.keywordBreast cancer-
dc.subject.keywordEribulin mesylate-
dc.subject.keywordKorean patients-
dc.subject.keywordRetrospective study-
dc.contributor.alternativeNameJeong, Joon-
dc.contributor.affiliatedAuthor정준-
dc.citation.volume54-
dc.citation.startPage121-
dc.citation.endPage126-
dc.identifier.bibliographicCitationBREAST, Vol.54 : 121-126, 2020-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.